Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Tardive Dyskinesia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Tardive Dyskinesia - Pipeline Review, H1 2015', provides an overview of the Tardive Dyskinesia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Tardive Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tardive Dyskinesia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Tardive Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tardive Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tardive Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tardive Dyskinesia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Tardive Dyskinesia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Tardive Dyskinesia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Tardive Dyskinesia Overview 6 Therapeutics Development 7 Pipeline Products for Tardive Dyskinesia - Overview 7 Pipeline Products for Tardive Dyskinesia - Comparative Analysis 8 Tardive Dyskinesia - Therapeutics under Development by Companies 9 Tardive Dyskinesia - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Tardive Dyskinesia - Products under Development by Companies 13 Tardive Dyskinesia - Companies Involved in Therapeutics Development 14 Auspex Pharmaceuticals, Inc. 14 Contera Pharma ApS 15 Medicure Inc. 16 Neurocrine Biosciences, Inc. 17 Synchroneuron Inc. 18 Tardive Dyskinesia - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 25 Drug Profiles 26 acamprosate calcium SR - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Drugs for Tardive Dyskinesia - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 dutetrabenazine ER - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Tardoxal - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 valbenazine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Tardive Dyskinesia - Recent Pipeline Updates 33 Tardive Dyskinesia - Dormant Projects 39 Tardive Dyskinesia - Product Development Milestones 40 Featured News & Press Releases 40 Oct 30, 2014: Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial for SD-809 in Tardive Dyskinesia 40 Oct 30, 2014: Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia 40 Oct 20, 2014: Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854 41 Aug 13, 2014: Medicure Provides Update on Tardoxal and TEND-TD Study 42 Jul 17, 2014: Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial for SD-809 in Tardive Dyskinesia 43 Feb 24, 2014: Synchroneuron Announces First Patient Dosed in Phase 2 Tardive Dyskinesia Clinical Trial 43 Jan 09, 2014: Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854 44 Jan 06, 2014: Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study 46 Sep 09, 2013: Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia 47 Jul 01, 2013: Neurocrine Announces Completion Of Enrollment Into Kinect Study For Treatment Of Tardive Dyskinesia 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 52 Disclaimer 52
List of Tables Number of Products under Development for Tardive Dyskinesia, H1 2015 7 Number of Products under Development for Tardive Dyskinesia - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Tardive Dyskinesia - Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 14 Tardive Dyskinesia - Pipeline by Contera Pharma ApS, H1 2015 15 Tardive Dyskinesia - Pipeline by Medicure Inc., H1 2015 16 Tardive Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H1 2015 17 Tardive Dyskinesia - Pipeline by Synchroneuron Inc., H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 21 Number of Products by Stage and Mechanism of Action, H1 2015 23 Number of Products by Stage and Route of Administration, H1 2015 24 Number of Products by Stage and Molecule Type, H1 2015 25 Tardive Dyskinesia Therapeutics - Recent Pipeline Updates, H1 2015 33 Tardive Dyskinesia - Dormant Projects, H1 2015 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
